ReviewSeminars in nephrology2018
Personalized Management of Bone and Mineral Disorders and Precision Medicine in End-Stage Kidney Disease.
Review in Seminars in nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Recent applications of quantitative systems pharmacology and machine learning models across diseases.Journal of pharmacokinetics and pharmacodynamics · 2022Pooled it
- Association of blood urea nitrogen to high-density lipoprotein ratio with all-cause and cardiovascular mortality in individuals with mildly reduced eGFR.Clinics (Sao Paulo, Brazil) · 2026Article
- Microbial Influences on Calcium-Phosphorus Homeostasis and Metabolic Bone Diseases: A Bidirectional Mendelian Randomisation Study on the Gut-Bone Axis.Journal of cellular and molecular medicine · 2025Article
- Review
- AI-Powered Renal Diet Support: Performance of ChatGPT, Bard AI, and Bing Chat.Clinics and practice · 2023Article
- 3D MRI PD-SPACE-COR Predicting Safety Margin for Coracoid Transfer.Orthopaedic surgery · 2023Article
- Biological Activity of Different Forms of Oxidized Parathyroid Hormone.International journal of molecular sciences · 2022Review
- Use of Artificial Intelligence to Identify New Mechanisms and Approaches to Therapy of Bone Disorders Associated With Chronic Kidney Disease.Frontiers in medicine · 2022Review
- Mathematical Models of Parathyroid Gland Biology: Complexity and Clinical Use.Frontiers in nephrology · 2022Review
- Development of a quantitative systems pharmacology model of chronic kidney disease: metabolic bone disorder.American journal of physiology. Renal physiology · 2021Article
- Personalized Prediction of Short- and Long-Term PTH Changes in Maintenance Hemodialysis Patients.Frontiers in medicine · 2021Article
- Nursing Personnel in the Era of Personalized Healthcare in Clinical Practice.Journal of personalized medicine · 2020Review
- New Intravenous Calcimimetic Agents: New Options, New Problems. An Example on How Clinical, Economical and Ethical Considerations Affect Choice of Treatment.International journal of environmental research and public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Chronic kidney disease mineral bone disorder (CKD-MBD) is common in end-stage renal disease and is associated with an increased risk of cardiovascular morbidity and mortality. Mainstays of treatment include decreasing serum phosphorus level toward the normal range with dietary interventions and phosphate binders and treating increased parathyroid hormone levels with activated vitamin D and/or calcimimetics. There is significant variation in serum levels of mineral metabolism markers, intestinal absorption of phosphorus, and therapeutic response among individual patients and subgroups of patients with end-stage renal disease. This variation may be partly explained by polymorphisms in genes associated with calcium and phosphorus homeostasis such as the calcium-sensing receptor gene, the vitamin D-binding receptor gene, and genes associated with vascular calcification. In this review, we discuss how personalized medicine may be used for the management of CKD-MBD and how it ultimately may lead to improved clinical outcomes. Although genetic variants may seem attractive targets to tailor CKD-MBD therapy, complete understanding of how these polymorphisms function and their clinical utility and applicability to personalized medicine need to be determined.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.